About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Leyden Laboratories B.V. (the "Company" or "Leyden Labs") today announced it has raised $70M in funding to advance its ...

According to MoEngage’s Email Benchmark Report for 2025 and Beyond, personalized emails outperform the generic ones. The ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

"Tenvie was purpose-built to apply deep biological and chemical insights to address critical disease pathways,” said Paul L. Berns, Managing Director at ARCH Venture Partners and Executive Chair of ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Funding will propel Leyden Labs' non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The programs are based on Leyden Labs' Mucosal Protection Platform utilizing ...

Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II drugs for Uveal Melanoma have a 29% phase transition success ...

Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Hepatocellular Carcinoma.